PMC:7074432 / 2393-3512
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
126 | 214-221 | Gene | denotes | NSP1–16 | Gene:10045 |
127 | 62-70 | Species | denotes | SARS-CoV | Tax:694009 |
128 | 267-270 | Species | denotes | CoV | Tax:11118 |
129 | 394-397 | Species | denotes | CoV | Tax:11118 |
130 | 503-511 | Species | denotes | SARS-CoV | Tax:694009 |
131 | 1083-1092 | Species | denotes | 2019-nCoV | Tax:2697049 |
132 | 578-586 | Species | denotes | SARS-CoV | Tax:694009 |
133 | 310-319 | Chemical | denotes | lopinavir | MESH:D061466 |
134 | 347-357 | Chemical | denotes | saquinavir | MESH:D019258 |
135 | 517-520 | Chemical | denotes | pro | MESH:D011392 |
136 | 597-606 | Chemical | denotes | lopinavir | MESH:D061466 |
137 | 656-659 | Chemical | denotes | HKU | |
138 | 679-688 | Chemical | denotes | Ritonavir | MESH:D019438 |
139 | 709-718 | Chemical | denotes | lopinavir | MESH:D061466 |
140 | 923-942 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
141 | 1002-1023 | Chemical | denotes | lopinavir + ritonavir | MESH:C558899 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T143 | 62-70 | SP_10 | denotes | SARS-CoV |
T142 | 146-154 | MOP:0000780 | denotes | cleaving |
T141 | 214-218 | PR:000014815 | denotes | NSP1 |
T140 | 271-281 | UBERON:0000104 | denotes | life cycle |
T131 | 679-688 | DG_30 | denotes | Ritonavir |
T130 | 709-718 | DG_23 | denotes | lopinavir |
T139 | 310-319 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T138 | 333-342 | CHEBI:35222;CHEBI:35222 | denotes | inhibitor |
T137 | 347-357 | CHEBI:63621;DG_32;CHEBI:63621 | denotes | saquinavir |
T136 | 381-390 | CHEBI:35222;CHEBI:35222 | denotes | inhibitor |
T135 | 479-489 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T134 | 503-511 | SP_10 | denotes | SARS-CoV |
T133 | 578-586 | SP_10 | denotes | SARS-CoV |
T132 | 597-606 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T129 | 923-932 | DG_23 | denotes | lopinavir |
T128 | 933-942 | DG_30 | denotes | ritonavir |
T127 | 1002-1011 | CHEBI:31781;DG_23;CHEBI:31781 | denotes | lopinavir |
T126 | 1014-1023 | DG_30 | denotes | ritonavir |
T125 | 1083-1092 | SP_7 | denotes | 2019-nCoV |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 204-212 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T2 | 748-751 | Body_part | denotes | HIV | http://purl.org/sig/ont/fma/fma278683 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T15 | 62-70 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T16 | 503-511 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T17 | 578-586 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T14 | 76-78 | http://purl.obolibrary.org/obo/CLO_0052906 | denotes | CL |
T15 | 757-758 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T16 | 880-881 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T24 | 9-18 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T25 | 204-212 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T26 | 289-308 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T28 | 298-308 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T29 | 310-319 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T30 | 333-342 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T31 | 347-357 | Chemical | denotes | saquinavir | http://purl.obolibrary.org/obo/CHEBI_63621 |
T32 | 381-390 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
T33 | 479-489 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T34 | 597-606 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T35 | 709-718 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T36 | 923-942 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T37 | 923-932 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T38 | 933-942 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T39 | 1002-1011 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T40 | 1014-1023 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T41 | 1043-1061 | Chemical | denotes | protease inhibitor | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
T43 | 1052-1061 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T17 | 0-18 | Sentence | denotes | Protease inhibitor |
T18 | 19-282 | Sentence | denotes | There are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), which carry out important functions in the CoV life cycle. |
T19 | 283-1119 | Sentence | denotes | Among protease inhibitors, lopinavir was the most inhibitor and saquinavir was the least powerful inhibitor of CoV protease.[13] In molecular dynamic studies, flap closing was observed when these inhibitors bound to the SARS-CoV 3CL (pro).[14] Hong Kong University researchers demonstrated anti-SARS-CoV action of lopinavir at concentration of 4 μg/ml in vitro against the HKU-39849 isolate.[15] Ritonavir boosting along with lopinavir is used in the management of HIV.[16] A clinical study at the same Hong Kong University suggests that even after adjustment for LDH level (possible confounder), a significant association was seen between lopinavir/ritonavir use and better outcome.[15] As per the current guidelines, lopinavir + ritonavir is the recommended protease inhibitor for the treatment of 2019-nCoV (weak recommendation).[17] |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
32201439-18706430-47219410 | 523-525 | 18706430 | denotes | 14 |
32201439-14985565-47219411 | 675-677 | 14985565 | denotes | 15 |
32201439-16827606-47219412 | 753-755 | 16827606 | denotes | 16 |
32201439-14985565-47219413 | 967-969 | 14985565 | denotes | 15 |
32201439-32029004-47219414 | 1116-1118 | 32029004 | denotes | 17 |
T5394 | 523-525 | 18706430 | denotes | 14 |
T51142 | 675-677 | 14985565 | denotes | 15 |
T94741 | 753-755 | 16827606 | denotes | 16 |
T99431 | 967-969 | 14985565 | denotes | 15 |
T46519 | 1116-1118 | 32029004 | denotes | 17 |